Publication
Are Anti-Ro52 Antibodies Associated with Pulmonary Involvement in Scleroderma?
| dc.contributor.author | Ferreira, J. | |
| dc.contributor.author | Almeida, I. | |
| dc.contributor.author | Marinho, A. | |
| dc.contributor.author | Cerveira, C. | |
| dc.contributor.author | Vasconcelos, C. | |
| dc.date.accessioned | 2012-11-07T10:26:55Z | |
| dc.date.available | 2012-11-07T10:26:55Z | |
| dc.date.issued | 2012 | |
| dc.description.abstract | Abstract Introduction: The presence of anti-Ro52 antibodies has been reported in a wide variety of autoimmune diseases, particularly in myositis, scleroderma and autoimmune liver diseases. Clinical significance of anti-Ro52 antibodies remains controversial. Studies are lacking in clarifying the association of anti-Ro52 with pulmonary involvement in scleroderma. Objectives: To determine if anti-Ro52 antibodies are associated with pulmonary involvement (interstitial, indirect pulmonary hypertension, or both) in scleroderma. Methods: Single center, retrospective study based on immunoblotting panel analysis and patients clinical records. Pulmonary manifestations were sub-grouped in: 1) interstitial (alveolitis and/or fibrosis), 2) pulmonary artery systolic pressure (PASP) ≥40 mmHg plus interstitial pulmonary disease, and 3) isolated PASP≥40 mmHg (purely vascular). Results: Our scleroderma cohort included 200 patients, of which 137 had immunoblotting panels with anti-Ro52 reactivity analysis. The search was conducted between January 2010 and July 2011. The frequency of pulmonary manifestations in patients with positive anti-Ro52 antibodies was 67.7% (n=31), and 60% (n=24) in the negative anti-Ro52 group, showing no significant differences between groups (p=0.621). Still no significant differences were found when pulmonary manifestations were evaluated according to the subgroups (p=0.525). Sensitivity, specificity, positive and negative predictive values of anti-Ro52 reactivity for determining pulmonary involvement in scleroderma were low. Conclusion: No association was found between positive anti-Ro52 antibodies and pulmonary involvement in scleroderma. | por |
| dc.identifier.citation | Ferreira JP, Almeida I, Marinho A, Cerveira C, Vasconcelos C (2012) Are Anti-Ro52 Antibodies Associated with Pulmonary Involvement in Scleroderma?. J Pulmonar Respirat Med 2:116. doi:10.4172/2161-105X.1000116 | por |
| dc.identifier.other | doi:10.4172/2161-105X.1000116 | |
| dc.identifier.uri | http://hdl.handle.net/10400.16/1328 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | OMICS Publishing Group | por |
| dc.relation.publisherversion | http://dx.doi.org/10.4172/2161-105X.1000116 | por |
| dc.subject | Anti-Ro52 antibodies | por |
| dc.subject | Pulmonary involvement | por |
| dc.subject | Scleroderma | por |
| dc.title | Are Anti-Ro52 Antibodies Associated with Pulmonary Involvement in Scleroderma? | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.title | J Pulmonar Respirat Med | por |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |